MarketInOut Stock Screener Log In | Sign Up

UCB S.A.

BRU • Healthcare • Biotechnology • Quote as of 10/30/2026
UCB S.A. stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeBRU
Market Capitalization51,384 mln
Float117 mln
Earnings Date02/26/2027

EPS

11.32
Robust

P / E

24.86
Premium valuation

Piotroski F-Score

9 / 9
Exceptional

Beneish M-Score

-2.43
Borderline

1-Year Forecast

291.58
Fairly priced

Relative Strength

99 / 100
Top performer

Business Description

UCB is a Belgium-based medicine company founded in 1925 that focuses on treating neurological and immune system conditions. Its product range covers epilepsy, Parkinson's disease, rheumatoid arthritis, psoriasis, osteoporosis, and several rare disorders, among others. The company sells well-known medicines such as Cimzia, Vimpat, Neupro, and Zyrtec, while also advancing a pipeline of new treatments targeting conditions like Alzheimer's disease, lupus, and certain genetic disorders. In addition to developing and selling its own products, UCB also provides manufacturing services to other companies.

Key Fundamentals

EPS11.32
P/E24.86
ROE20.44
RPS44.76
ROIC17.44
ROA11.76
Interest Cover15.68
EBITDA, mln3,333
EV / EBITDA12.93
EV / EBIT15.92
Revenue, mln8,524
EV / Revenue5.05

Quote Details

Last 281.40
Change 1.4 (0.5%)
Open 281.70
Volume 279,985
Turnover 78,787,776
Average Volume 317,260

Financial Ratios

Pre-Tax Profit Margin30
Leverage Ratio1.77
Current Ratio1.20
Price / Book3.36
Price / Tangible Book86.54
Price / Cash Flow27.05
Price / Free Cash Flow27.57
Debt / Equity0.31
Price / Sales4.67
PEG Ratio1.44

Financial Strength

Altman Z-Score4.8
Piotroski F-Score 9 / 9
Beneish M-Score-2.43
Price to Intrinsic Value2.07
Price to Lynch Fair Value2.04
Price to Graham Number8.33
1-Year Target Price291.58
Shiller PE Ratio42.55

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.19% 86 / 100   
1 Month 39.79% 99 / 100   
2 Months 12.47% 92 / 100   
6 Months 20.88% 88 / 100   
1 Year 30.25% 83 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog